EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.02
-0.15 (-4.73%)
▼
5d:
-10.65%
30d:
-20.32%
90d:
-25.25%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 20, 2026
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EVAX is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EVAX is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.02, which is considered oversold relative to its 30-day fair value range of $3.14 to $3.58. From a valuation perspective, the stock is trading at a discount (Forward PE: 75.5) compared to its historical average (86.8). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVAX is in a uptrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.25 (+272.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVAX is in a uptrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.25 (+272.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.14 -
$3.58
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 272.5% below Wall St target ($11.25)
- WARNING: Recommendation downgraded due to -10.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.14 -
$3.58
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.23
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
75.50
Wall Street Target
$11.25
(+272.5%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
75.5 vs 86.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$2.88
(-5%)
2-Year Target
$2.75
(-9%)
3-Year Target
$2.62
(-13%)
3-Yr Target (if PE normalizes)
(PE: 76→87)
$3.01
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 75.5 to 86.8
Stabilization Target:
$3.47
(+15.0%)
PE Expansion Potential:
+15.0%
Share & Embed Analysis
Last updated: July 14, 2026 3:06 AM ET
Data refreshes hourly during market hours. Next update: 4:06 AM
Data refreshes hourly during market hours. Next update: 4:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |